GT Biopharma (GT Biopharma (GTBP)) is leaning into artificial intelligence to speed up the way it discovers and designs cancer drugs. On Monday, the clinical-stage immuno-oncology company said its recently deployed AI tools are already making a difference in productivity and pipeline efficiency, and it expects to have new drug candidates ready for pre-IND development by 2027.
The company specializes in natural killer cell engagers built on its proprietary TriKE platform. Its lead programs, GTB-3650 and GTB-5550, are moving through Phase 1 studies this year. But the real story here is what AI is doing for the next generation of assets.
Michael Breen, executive chairman and CEO, said the company is focusing on next-generation candidates that could offer shorter development timelines, better odds of clinical success, and lower costs. AI is the engine behind that push.
How AI Is Changing Drug Design
GT Biopharma is using AI-guided sequence and structural analyses to identify new tumor-targeting engagers and multi-domain proteins. The goal is to find molecules with favorable characteristics like binding affinity, stability, and overall developability. The company says these tools help researchers prioritize molecules that are more likely to succeed beyond the discovery stage.
AI is also being used to optimize molecular engineering. That means tweaking domain orientation, linker design, and spatial architecture to improve binding, promote productive immune synapse formation, and reduce structural issues that could mess with potency, manufacturing, or consistency.
Structural Modeling to Streamline Development
In later-stage discovery work, GT Biopharma applies AI-based structural modeling to evaluate factors like surface exposure, steric compatibility, and assay performance. The modeling helps refine drug constructs before they move into more resource-intensive in vitro and in vivo studies. It’s a way to catch problems early and avoid wasting time and money on candidates that are unlikely to pan out.
GT Biopharma shares were up 0.38% at $0.48 during premarket trading on Monday.
.jpeg)
